380 related articles for article (PubMed ID: 32029634)
1. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
3. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
5. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
7. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal rearrangements in uveal melanoma: Chromothripsis.
van Poppelen NM; Yavuzyigitoglu S; Smit KN; Vaarwater J; Eussen B; Brands T; Paridaens D; Kiliç E; de Klein A
Genes Chromosomes Cancer; 2018 Sep; 57(9):452-458. PubMed ID: 29726589
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling of Metastatic Uveal Melanoma Shows Frequent Coexisting BAP1 or SF3B1 and GNAQ/GNA11 Mutations and Correlation With Prognosis.
Isaacson AL; Sompallae RR; Guseva NV; Bellizzi AM; Bossler AD; Ma D
Am J Clin Pathol; 2022 Aug; 158(2):177-186. PubMed ID: 35212356
[TBL] [Abstract][Full Text] [Related]
11. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
[TBL] [Abstract][Full Text] [Related]
12. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
14. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
15. Monosomy 3 Influences Epithelial-Mesenchymal Transition Gene Expression in Uveal Melanoma Patients; Consequences for Liquid Biopsy.
Soltysova A; Sedlackova T; Dvorska D; Jasek K; Chokhachi Baradaran P; Horvathova Kajabova V; Demkova L; Buocikova V; Kurucova T; Lyskova D; Furdova A; Minarik G; Babal P; Dankova Z; Smolkova B
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348918
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.
de Lange MJ; van Pelt SI; Versluis M; Jordanova ES; Kroes WG; Ruivenkamp C; van der Burg SH; Luyten GP; van Hall T; Jager MJ; van der Velden PA
Oncotarget; 2015 Nov; 6(35):37824-35. PubMed ID: 26462151
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations.
Yavuzyigitoglu S; Mensink HW; Smit KN; Vaarwater J; Verdijk RM; Beverloo B; Brüggenwirth HT; van Marion R; Dubbink HJ; Paridaens D; Naus NC; de Klein A; Kiliç E;
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):2232-9. PubMed ID: 27116551
[TBL] [Abstract][Full Text] [Related]
19. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Johansson P; Aoude LG; Wadt K; Glasson WJ; Warrier SK; Hewitt AW; Kiilgaard JF; Heegaard S; Isaacs T; Franchina M; Ingvar C; Vermeulen T; Whitehead KJ; Schmidt CW; Palmer JM; Symmons J; Gerdes AM; Jönsson G; Hayward NK
Oncotarget; 2016 Jan; 7(4):4624-31. PubMed ID: 26683228
[TBL] [Abstract][Full Text] [Related]
20. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
